Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
AGN > SEC Filings for AGN > Form 8-K on 14-Jan-2014All Recent SEC Filings

Show all filings for ALLERGAN INC



Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure.

On January 14, 2014, the United States District Court for the Eastern District of Texas (the "Court") ruled in favor of Allergan, Inc. (the "Company") in a patent infringement matter concerning the Company's Lumigan® (bimatoprost ophthalmic solution) 0.01% product ("Lumigan® 0.01%").

The Company initiated the lawsuit under the Drug Price Competition and Patent Term Restoration Act, commonly known as the Hatch-Waxman Act, after the defendants, Sandoz Inc., Lupin Ltd., Lupin Pharmaceuticals Inc., Hi-Tech Pharmacal Co., Inc., Watson Laboratories, Inc., Watson Pharmaceuticals, Inc., and Watson Pharma, Inc. (collectively, the "Defendants"), sought to market a generic version of Lumigan® 0.01%, which was first approved by the U.S. Food and Drug Administration in 2010 for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The Court's ruling found the asserted claims of U.S. Patent Numbers 7,851,504, 8,278,353, 8,299,118, 8,309,605 and 8,338,479 (collectively, the "Patents") are not invalid and are infringed by the Defendants' proposed generic drug products. As part of the ruling, the Court granted the Company's request for a permanent injunction enjoining the Defendants from marketing their proposed generic drug products until the expiration of the Patents.

  Add AGN to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for AGN - All Recent SEC Filings
Copyright © 2015 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.